Aytu BioScience

106 articles with Aytu BioScience

• Aytu BioScience Provides Fiscal Fourth Quarter And Year-End 2017 Business Update

  8/31/2017

• Aytu BioScience Announces Split-Adjusted Trading Of Its Common Stock

  8/29/2017

• Aytu BioScience Announces Reverse Split Of Its Common Stock

  8/28/2017

• Aytu BioScience To Provide Fiscal Fourth Quarter And Year-End 2017 Business Update

  8/24/2017

• Aytu BioScience Announces Closing Of $11.8 Million Private Placement

  8/16/2017

• Aytu BioScience Announces $11.5 Million Private Placement

  8/14/2017

• Aytu BioScience Expands MiOXSYS Distribution Network With A Fertility-Focused Company In Over 20 Countries In Europe

  7/13/2017

• Aytu BioScience Presents Clinical Findings For Its MiOXSYS System At 33rd Annual Meeting Of The European Society Of Human Reproduction And Embryology

  7/5/2017

• Aytu BioScience Announces The Appointment Of Gregory A. Gould As Permanent Chief Financial Officer

  6/19/2017

• Aytu BioScience Presents New Research Findings For Its Natesto Testosterone Nasal Gel At 112th American Urological Association Annual Meeting

  5/17/2017

• Aytu BioScience Presents New Research Findings For Its Mioxsys System At 112th American Urological Association Annual Meeting

  5/15/2017

• Aytu BioScience Provides Third Quarter Fiscal 2017 Business Update

  5/12/2017

• Aytu BioScience Announces The Acquisition Of Nuelle, Developer And Marketer Of Fiera Female Personal Care Device

  5/9/2017

• Aytu BioScience To Provide Fiscal Third Quarter 2017 Business Update

  5/3/2017

• Aytu BioScience Presents Latest Clinical Findings For Natesto At ENDO 2017, The National Endocrine Society's Annual Scientific Meeting

  4/4/2017

• Aytu BioScience Announces Divestiture Of Primsol To Allegis Holdings

  4/3/2017

• Aytu BioScience Announces Peer-Reviewed Publication Of Fourth Clinical Study Demonstrating The Utility Of MiOXSYS In The Assessment Of Male Infertility

  3/14/2017

• Aytu BioScience Completes Successful Warrant Tender Offer And Receives $2.2 Million From Exercise Of Warrants

  3/1/2017

• Aytu BioScience Announces Expansion Of U.S. Sales Team To Support Increasing Growth Of Natesto Prescriptions And Revenues

  2/22/2017

• Aytu BioScience Provides Second Quarter Fiscal 2017 Business Update and Financial Results

  2/10/2017